Angiocrine Bioscience
San Diego, California, United States · Biotechnology · 16 employees
Angiocrine Bioscience is a private, clinical stage engineered cell therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions. Our team is developing a pipeline of proprietary engineered endothelial cell (E-CEL® ) therapies for treating multiple life-threatening hemato-oncol
Funding history
- Series seed — $2.1M — Sep 2025
- Funding Round — $58.1M — Oct 2021
Recent signals
- Sep 05, 2025: Raised $2.1M in Series seed
- Oct 15, 2021: Raised $58.1M
See plans & pricing → Track Angiocrine Bioscience’s funding, hiring, and signals — with verified contacts — on Fundz.